Drugs / SNK-396
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05896969 | Apr 2023 → Feb 2024 | low density lipoprotein cholesterol, mild elevation of | Syneos Health | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNK-396 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05896969 ↗ |
| Route | Subcutaneous | “with SC doses of SNK-396” NCT05896969 ↗ |